Vaxart Files 8-K on Material Agreement; Details Undisclosed

TL;DR

**Vaxart filed an 8-K about a material agreement, but gave zero details, so investors are flying blind.**

AI Summary

Vaxart, Inc. filed an 8-K on January 16, 2024, indicating an "Entry into a Material Definitive Agreement" and "Other Events." While the filing confirms Vaxart's corporate details like its Delaware incorporation and South San Francisco address, it does not disclose the specifics of the material agreement or other events. This matters to investors because without details, it's impossible to assess the financial impact or strategic implications of this new agreement, leaving shareholders in the dark about potential opportunities or risks.

Why It Matters

This filing signals a significant corporate event for Vaxart, Inc. but provides no details, leaving investors unable to evaluate its potential positive or negative impact on the company's future performance or stock price.

Risk Assessment

Risk Level: medium — The lack of specific information about a 'Material Definitive Agreement' creates uncertainty and potential risk for investors, as the nature of the agreement is unknown.

Analyst Insight

A smart investor would await further disclosures from Vaxart, Inc. regarding the specifics of the 'Material Definitive Agreement' and 'Other Events' before making any investment decisions, as the current filing lacks critical information to assess impact.

Key Players & Entities

• Vaxart, Inc. (company) — the registrant filing the 8-K
• Delaware (company) — state of incorporation for Vaxart, Inc.
• South San Francisco, California (company) — location of Vaxart, Inc.'s principal executive offices
• 001-35285 (dollar_amount) — Vaxart's Commission File Number
• 59-1212264 (dollar_amount) — Vaxart's IRS Employer Identification No.
• (650) 550-3500 (dollar_amount) — Vaxart's business phone number

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock , $0.0001 par value   VXRT   Th
• $0.65 — are (the "Common Stock"), at a price of $0.65 per share (the "Offering"). The total p
• $10 million — Capital for the Shares is approximately $10 million. The Offering is scheduled to close on

Filing Documents

• vxrt20240116_8k.htm (8-K) — 32KB
• ex_615538.htm (EX-5.1) — 7KB
• ex_615503.htm (EX-10.1) — 124KB
• ex_615633.htm (EX-99.1) — 14KB
• z01.jpg (GRAPHIC) — 12KB
• z02.jpg (GRAPHIC) — 12KB
• 0001437749-24-001419.txt ( ) — 378KB
• vxrt-20240116.xsd (EX-101.SCH) — 3KB
• vxrt-20240116_def.xml (EX-101.DEF) — 11KB
• vxrt-20240116_lab.xml (EX-101.LAB) — 15KB
• vxrt-20240116_pre.xml (EX-101.PRE) — 11KB
• vxrt20240116_8k_htm.xml (XML) — 2KB

01.           Entry into a Material Definitive Agreement

Item 1.01.           Entry into a Material Definitive Agreement.   On January 16, 2024, Vaxart, Inc. (the "Company") entered into a securities purchase agreement (the "Securities Purchase Agreement") with RA Capital Healthcare Fund, L.P ("RA Capital").   Pursuant to the Securities Purchase Agreement, RA Capital agreed to purchase, and the Company agreed to issue and sell to RA Capital 15,384,615 shares (the "Shares") of common stock of the Company, par value $0.0001 per share (the "Common Stock"), at a price of $0.65 per share (the "Offering"). The total purchase price payable by RA Capital for the Shares is approximately $10 million. The Offering is scheduled to close on or about January 18, 2024 (the "Closing Date"), subject to customary closing conditions.   The Securities Purchase Agreement contains customary representations, warranties and agreements by the Company and customary conditions to closing, obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Securities Purchase Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by the contracting parties.   The Offering is being made pursuant to the Company's shelf registration statement on Form S-3 (File No. 333-270671), which was declared effective by the Securities and Exchange Commission (the "Commission") on May 5, 2023, including the prospectus contained therein, as well as a prospectus supplement to be filed with the Commission on or before the Closing Date.   The Securities Purchase Agreement is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference. The description of the Securities Purchase Agreement in this Current Report is a summary and is qualified in its entirety by the terms of t

01.           Other Events

Item 8.01.           Other Events.   On January 16, 2024, the Company issued a press release relating to the Offering. A copy of the press release is attached as Exhibits 99.1 to this Current Report and is incorporated by reference herein.  

01.           Financial Statements and Exhibits

Item 9.01.           Financial Statements and Exhibits.   (d) Exhibits .   Exhibit Number Description     5.1 Opinion of Thompson Hine LLP.     10.1 Securities Purchase Agreement, dated January 16, 2024, by and between Vaxart, Inc. and RA Capital Healthcare Fund, L.P.     23.1 Consent of Thompson Hine LLP (included in Exhibit 5.1).     99.1 Press Release, dated January 16, 2024.     104 Cover Page Interactive Data File (embedded within Inline XBRL document).        

SIGNATURES

SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.       VAXART, INC.     Dated: January 16, 2024     By: /s/ MICHAEL J. FINNEY     Michael J. Finney, Ph.D.     Interim Chief Executive Officer        

View Full Filing

View this 8-K filing on SEC EDGAR